Key facts
- Human Life CORD’s last known valuation is $46.6M (Jan 2026).
- It has raised $31.0M; the latest was Later Stage VC ($12.3M) in Jan 2026.
- Notable investors include J-Startup, DBJ Capital, Alfresa Holdings, CafeGroup, Inabata — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Human Life CORD
- ·The full record, as it builds
Funding rounds
No funding rounds for Human Life CORD are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Human Life CORD
Developer of cell-based medicines designed for tissue repair and treatment of intractable diseases operating in the biotechnology industry. The company offers serum-free mesenchymal stromal cells derived from umbilical cords supported by proprietary manufacturing and storage technologies to preserve cell quality and scalability, enabling healthcare professionals to administer regenerative therapies aimed at repairing damaged tissues and addressing complex disease conditions.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2017
- Employees
- 28
- Website
- humanlifecord.com/
- Ownership
- Privately Held (backing)
Human Life CORD doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Human Life CORD shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Human Life CORD in its N-PORT filings yet. We sweep new filings monthly.